What’s the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.
Investors are always on the lookout for the next revolutionary technology or product. In recent times, this has…
After 1- and 6-Month Gains, Gene Editing Companies Await Q3 Results
As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in…
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
CRISPR Therapeutics AG -Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a…
Here Are 2 With Even More Upside Ahead
On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to…
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
An updated edition of the June 27, 2025, article. Genomics encompasses the study of a complete set of…